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Abstract
Background: Histone modification H4K20me3 and its methyltransferase SUV420H2 have been implicated in
suppression of tumorigenesis. The underlying mechanism is unclear, although H4K20me3 abundance increases
during cellular senescence, a stable proliferation arrest and tumor suppressor process, triggered by diverse
molecular cues, including activated oncogenes. Here, we investigate the function of H4K20me3 in senescence
and tumor suppression.
Results: Using immunofluorescence and ChIP-seq we determine the distribution of H4K20me3 in proliferating
and senescent human cells. Altered H4K20me3 in senescence is coupled to H4K16ac and DNA methylation
changes in senescence. In senescent cells, H4K20me3 is especially enriched at DNA sequences contained
within specialized domains of senescence-associated heterochromatin foci (SAHF), as well as specific families
of non-genic and genic repeats. Altered H4K20me3 does not correlate strongly with changes in gene expression
between proliferating and senescent cells; however, in senescent cells, but not proliferating cells, H4K20me3
enrichment at gene bodies correlates inversely with gene expression, reflecting de novo accumulation of H4K20me3 at
repressed genes in senescent cells, including at genes also repressed in proliferating cells. Although elevated
SUV420H2 upregulates H4K20me3, this does not accelerate senescence of primary human cells. However, elevated
SUV420H2/H4K20me3 reinforces oncogene-induced senescence-associated proliferation arrest and slows
tumorigenesis in vivo.
Conclusions: These results corroborate a role for chromatin in underpinning the senescence phenotype but
do not support a major role for H4K20me3 in initiation of senescence. Rather, we speculate that H4K20me3
plays a role in heterochromatinization and stabilization of the epigenome and genome of pre-malignant,
oncogene-expressing senescent cells, thereby suppressing epigenetic and genetic instability and contributing
to long-term senescence-mediated tumor suppression.
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Background
Cellular senescence is a stable proliferation arrest associ-
ated with an altered pro-inflammatory secretory pathway
and an important tumor suppressor mechanism [1, 2].
For example, in response to acquisition of an activated
oncogene, primary human cells enter a proliferation-
arrested senescent state (oncogene-induced senescence
(OIS)) [3–6]. Replicative senescence (RS) imposes an
upper limit on the proliferative capacity of normal cells
and also serves a tumor suppressor role [7, 8]. The al-
tered secretory pathway of senescent cells, the so-called
senescence associated secretory phenotype (SASP) [9–11],
also contributes to tumor suppression by promoting clear-
ance of senescent cells by the immune system [12–14].
Extensive chromatin changes are apparent in senescent
cells [5, 15–24]. Importantly, the chromatin structure of
senescent cells contributes to senescence-mediated tumor
suppression [5, 22]. Chromatin changes in senescent cells
are perhaps best illustrated by senescence-associated
heterochromatin foci (SAHF) [15]. These punctate het-
erochromatic foci have been proposed to promote silen-
cing of proliferation-promoting genes and/or dampen the
DNA damage response in senescent cells to maintain
cell viability [15, 25]. SAHF result from compaction of
individual chromosomes and are enriched in a number
of chromatin-associated proteins, namely histone vari-
ant macroH2a, HMGA proteins, and HP1 proteins
[15, 16, 22, 26, 27]. In addition, SAHF exhibit a lay-
ered structure comprised of an H3K9me3-rich core of
DNA that ordinarily replicates late in S phase in pro-
liferating cells surrounded by an outer H3K27me3-
rich domain [18].
Other studies have shown changes to the genome-
wide distribution of some histone and DNA modifica-
tions in senescent cells compared with proliferating cells.
In senescent cells, lamin B1 is degraded by autophagy
[28–31] and this is associated with chromatin changes
in and around those regions that, in proliferating
cells, interact with nuclear lamins, the so-called lamin
associated domains (LADs) [32]. For example, senescent
cells harbor large-scale domains of H3K4me3- and
H3K27me3-enriched “mesas” and H3K27me3-depleted
“canyons” [20]. Mesas form at LADs, whereas canyons
form mostly between LADs and are enriched in genes
and enhancers. Loss of gene-repressive H3K27me3 at
canyons correlates with up-regulation of key senes-
cence genes. Some DNA methylation changes are also
focused on LADs. Specifically, LADs undergo DNA
hypomethylation in senescent cells [21]. Conversely,
many repressed cell cycle genes gain DNA methyla-
tion flanking their promoter transcription start site
and this may contribute to repression of those genes
and stable senescence-associated proliferation arrest
[21]. Given these precedents, other histone and
chromatin modifications are also likely important in
senescence.
In this regard, the abundance of a specific histone
modification, H4K20me3, has been previously reported
to increase in senescent cells (both OIS and RS) [33],
prematurely aged (progeroid) cells [34], and physiologically
aged tissues [35]. Conversely, abundance of H4K20me3
and the enzyme primarily responsible for its deposition,
SUV420H2, decrease in cancer cells [36–40]. Moreover,
SUV420H2 suppresses the tumorigenicity of induced pluri-
potent stem cells and invasiveness of breast cancer cells
[40, 41]. Together, these data suggest a model whereby
SUV420H2 and H4K20me3 enforce a barrier to cell trans-
formation and tumorigenesis that is played out, at least in
part, in senescent cells and aged tissues [42]. In terms of
mechanism, H4K20me3 has been proposed to suppress
transcription and recombination and/or control telomere
elongation [41, 43–47]. A recent report showed that re-
cruitment of H4K20me3 and the enzyme primarily respon-
sible for its deposition, SUV420H2, to rRNA genes and
IAP repeats leads to chromatin compaction at these re-
peats during cell quiescence and differentiation [48].
However, the genomic distribution and function of
H4K20me3 in senescent cells has not been investigated.
Here, we combined an epigenomic profiling approach
and functional assays to better understand the role of
SUV420H2 and H4K20me3 in senescence. Based on
these data, we propose that elevated H4K20me3 in sen-
escent cells contributes, at least in part, to stabilization
of the senescent epigenome and genome, thereby stabil-
izing the senescent phenotype and, hence, long-term
senescence-mediated tumor suppression.
Results
Senescent cells accumulate elevated levels of H4K20me3
In order to investigate the potential contribution of
H4K20me3 to the senescence program, we first set out
to better characterize the regulation and distribution of
the mark in senescent cells in vitro. To accomplish this,
low passage proliferating primary human IMR90 fibro-
blasts were infected with either control retrovirus or a virus
encoding constitutively activated H-RAS (H-RASG12V) to
induce OIS. As expected, compared with control-infected
cells, cells expressing oncogenic H-RASG12V acquired an
enlarged, flattened, senescent morphology, accompanied
by an increase in senescence-associated β-galactosidase
(SA β-gal) activity (Fig. 1a; Additional file 1: Figure S1a). In
addition, the H-RASG12V-expressing cells underwent a
proliferative arrest as evidenced by a marked reduction in
5-ethynyl-2′-deoxyuridine (EdU) incorporation (Fig. 1b;
Additional file 1: Figure S1b). Consistent with a reduced
proliferative capacity, the H-RASG12V-expressing cells
also exhibited additional biochemical markers of cell
cycle exit, including decreased cyclin A expression and
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p16INK4a induction, further confirming senescence
(Fig. 1c). Concurrent with the onset of OIS, the mutant
H-RASG12V-expressing cells exhibited a progressive
increase in H4K20me3 abundance relative to total his-
tone H4 levels (Fig. 1d; Additional file 1: Figure S1c, d).
The observation that senescent cells harbor higher
levels of H4K20me3 than proliferating cells was further
confirmed using two additional validated antibodies in
both RS and OIS cells (Fig. 1e; Additional file 1: Figure
S1c, d). Consistent with previous reports [48–50],
H4K20me3 levels also increased in quiescent cells rela-
tive to proliferating cells, but to only a fraction of the
level observed in senescent cells (Fig. 1f ). Deposition of
H4K20me3 is predominantly catalyzed through the ac-
tivity of the histone methyltransferase SUV420H2 [46].
Consequently, we next sought to determine whether
the marked elevation of H4K20me3 levels in senescent
cells occurs as a consequence of increased expression
of SUV420H2. In fact, using an antibody to SUV420H2
validated against ectopic expression and knock down of
SUV420H2 (Additional file 1: Figure S1e, f ), only min-
imal changes in SUV420H2 protein expression were
observed in both RS and OIS cells (Fig. 1g). Thus, the
increase in H4K20me3 in senescent cells occurs inde-
pendent of increased expression of SUV420H2.
To further evaluate the increase of H4K20me3 in
senescence, OIS cells were subjected to indirect im-
munofluorescence staining for the modification. In
contrast to control-infected proliferating cells, which
exhibited a relatively uniform, faint, diffuse nuclear
staining pattern for H4K20me3, H-RASG12V infected
OIS cells displayed a more heterogeneous staining
pattern, often characterized by greater overall fluorescence
intensity and the presence of variably sized puncta
(Fig. 1h, i). A similar increased fluorescence intensity and
punctate nuclear pattern of H4K20me3 was detected in
RS cells relative to low passage proliferating (PD22) cells
(Additional file 1: Figure S1g).
In order to more quantitatively assess the abundance
of H4K20 modifications in senescent cells, total histones
were extracted from proliferating and RS cells and sub-
jected to analysis by quantitative mass spectrometry.
Whereas the trimethylated state accounted for only
0.2 % of all H4K20 residues in low passage proliferating
cells, the abundance of the modification increased 190-
fold to comprise 38 % of all H4K20 residues in RS cells
(Fig. 1j). Of note, the increased level of H4K20 trimethyla-
tion was accompanied by a decrease in H4K20 mono-
methylation (H4K20me1) and dimethylation (H4K20me2),
suggesting an overall conversion of H4K20me1/2 to
H4K20me3 in senescent cells.
To determine whether senescent cells also harbor ele-
vated levels of H4K20me3 under physiological conditions,
the abundance of the modification was assessed in pri-
mary human tissues containing senescent cells. Human
benign melanocytic nevi, neoplastic lesions of the skin
comprised largely of OIS melanocytes [3, 51], were sub-
jected to immunohistochemical evaluation of H4K20me3
abundance. Compared with the largely non-senescent
keratinocytes and Melan-A-expressing melanocytes within
the epidermal layer, senescent melanocytes residing
within the body of the nevus displayed higher levels
of H4K20me3 (Fig. 1k). This suggests that increased
H4K20me3 is a bona fide epigenetic feature of cellular
senescence in vivo.
A specialized distribution of H4K20me3 in senescent cells
Since H4K20me3 shows such a marked increase in
senescent cells, we next wanted to know its nuclear and
genomic distribution in senescent cells. First, we analyzed
its distribution throughout the nucleus by immunofluor-
escence staining. The distribution of H4K20me3 in OIS
cells showed no obvious relationship to some nuclear foci
characteristic of senescent cells, namely PML nuclear bod-
ies and DNA damage foci (γH2AX and 53BP1; Fig. 2a–c)
[52–54]. However, H4K20me3 in senescent cells revealed
(See figure on previous page.)
Fig. 1 Senescent cells accumulate elevated levels of H4K20me3 in vitro and in vivo. a Quantification of SA β-galactosidase-positive (SA β-gal+)
IMR90 cells 3–12 days after infection with either empty vector control (CON) or H-RASG12V virus. b Cells from a were pulse labeled with
5-ethynyl-2′-deoxyuridine (EdU) and positive cells scored. c Western blot of indicated proteins in whole cell extracts of cells from a. d
Western blot of H4K20me3 and histone H4 in whole cell extracts from c, normalized for total histone H4 content. e Western blot of histone H4
and indicated H4K20 modifications from whole cell extracts of proliferating (PRO), replicative senescent (RS), control-infected proliferating (CON) and
H-RASG12V-infected senescent (OIS) IMR90 cells, normalized for total histone H4 content. f Western blot of H4K20me3 and histone H4 from whole cell
extracts of proliferating (PRO), RS and quiescent (QUI) IMR90 cells, normalized for total histone H4 content; (s) and (l) denote short and long
autoradiographic exposures, respectively. Experiments in a–f are representative of at least five similar experiments. g Western blot of SUV420H2 and
GAPDH from whole cell extracts of PRO, RS, CON, and OIS cells. h Immunofluorescent images of H4K20me3 staining in CON and OIS cells 12 days after
infection. i Quantitative image analysis of H4K20me3 immunofluorescence in CON and OIS cells (181 CON and 129 OIS cells were scored). j Relative
percentages of the different methylation states of H4K20 in PRO and RS cells as determined by quantitative mass spectrometry; error bars
represent standard error of the mean. k Immunohistochemical images of human melanocytic nevus (N) and overlaying epidermis (E) stained
with antibodies against Melan-A and H4K20me3. The arrow indicates a non-nevus epidermal melanocyte. Data are representative of at least
ten different human nevi
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considerable spatial overlap with SAHF (Fig. 2d) [15]. Line
scan analysis of proliferating and senescent cell nuclei fur-
ther confirmed the co-localization of H4K20me3 foci and
SAHF in senescent cells (Fig. 2e). Moreover, in senescent
cells, H4K20me3 co-localized in foci with H3K9me3, a
histone modification that is highly enriched in those
regions of the genome that replicate late in S phase in pro-
liferating cells and are also folded into the core of SAHF
in senescent cells (Fig. 2f, g) [18]. Similar results were
obtained with RS cells (data not shown).
To define the genomic distribution of H4K20me3
at higher resolution, we applied chromatin immuno
precipitation-sequencing (ChIP-seq), using two inde-
pendent antibodies highly specific for H4K20me3
(Additional file 1: Figures S1c, d and S2a, b; Additional file
2: Table S1) and an antibody to total histone H4, to prolif-
erating and RS cells. Although the overlap of peaks
obtained with the two antibodies was significant in both
proliferating and RS cells, the extent of overlap was
much greater in RS cells. Subsequent analyses were
geared towards understanding the role of H4K20me3 in
senescent cells. Since H4K20me3 has previously been
reported to be enriched at constitutive heterochroma-
tin, including telomeres [47, 49, 55–57], we first consid-
ered the possibility that increased H4K20me3 in
senescent cells is largely localized to these regions.
However, quantitative analysis revealed no enrichment
in senescent cells compared with proliferating cells of
ChIP-seq reads aligning to TTAGGG telomeric repeat
sequences, regardless of whether the number of reads
was normalized to input chromatin or histone H4 ChIP
(to correct for any effect due to shortened telomeres in
RS cells; Fig. 3a). Indeed, there was a tendency for
H4K20me3 at these regions to decrease, although this
was not significant. Similarly, H4K20me3 decreased, ra-
ther than increased, at subtelomeric regions (Additional
file 1: Figure S3a). Moreover, ChIP-quantitative PCR
(qPCR) to determine H4K20me3 enrichment in the
17p and 18q subtelomeric repeats close to the telo-
meric ends also showed no increase in senescent cells
(Fig. 3b, c) and, in fact, a significant twofold decrease
close to the chromosome 17p end (Fig. 3b). Taken
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together, these results indicate that the increase in
H4K20me3 in senescent cells is not due to its increase
at telomeric or subtelomeric sequences.
To map regions of statistically significant H4K20me3
outside of these highly repetitive sequences, domains of
enrichment over background histone H4 (i.e., peaks)
were identified using SICER. Only significant peaks iden-
tified with both H4K20me3 antibodies from the two
independent RS experiments were considered specific
and evaluated in subsequent analyses. In total, 2836
H4K20me3 peaks were identified in proliferating cells,
whereas senescent cells contained 35,535 peaks (Fig. 3d).
Although the mean peak length was unchanged between
proliferating and senescent cells (Additional file 1: Figure
S3b), the senescent H4K20me3 peaks spanned a consid-
erably larger portion of the genome (38 Mb) than the
peaks in proliferating cells (3 Mb) (Fig. 3e). An increase
in the number of H4K20me3 peaks and the number of
base pairs covered by H4K20me3 was also observed in
OIS cells (Additional file 1: Figures S2c, d and S3c, d).
To compare the spatial distribution of H4K20me3
across the genome between proliferating and RS cells,
regions of H4K20me3 differential enrichment between
the intersection of the proliferating and intersection of
the RS replicates were computed using DiffBind [58].
Diffbind uses edgeR to identify significantly differentially
bound sites between two conditions, with multiple repli-
cates per condition. In total, 22,955 statistically signifi-
cant peaks of H4K20me3 differential enrichment were
identified between the proliferating and RS cells (Fig. 3d).
These peaks spanned 41 million total base pairs (Fig. 3e),
accounting for approximately 1.4 % of the human genome,
with a mean peak length of 1659 bp (Additional file 1:
Figure S3b). Consistent with the previous intersection
analysis, the vast majority of the 22,955 differentially
enriched H4K20me3 peaks identified between the prolif-
erating and RS states were more highly enriched in RS
compared with proliferating cells (Fig. 3f ). Similar
results were obtained in OIS cells (Additional file 1:
Figure S3c–e). Thus, the accumulation of H4K20me3
in senescent cells, previously observed by western blot,
immunofluorescence, and mass spectrometry, is similarly
observed by ChIP-seq.
In light of the previous immunofluorescence data
showing co-localization of H4K20me3 and H3K9me3 in
senescent cells (Fig. 2f ), we first compared the genomic
distribution of H4K20me3 with the genomic distribution
of H3K9me3 in senescent cells, previously published by
Narita and coworkers [18]. Considering either peaks of
H4K20me3 determined by DiffBind or base pairs within
the two antibody intersection, there was a highly signifi-
cant two- to threefold enrichment of H4K20me3 overlap
with H3K9me3 in RS cells and a three- to sixfold enrich-
ment in OIS cells (Fig. 3g, h; Additional file 1: Figure
S3f, g). Strikingly, the mean enrichment profiles of RS
and OIS H4K20me3 at a composite H3K9me3 peak (as-
sembled from all H3K9me3 peaks [18]) were coincident
with H3K9me3 and comparable to the composite ana-
lysis of the immunofluorescence imaging data (Fig. 3i,
and compare to Fig. 2g). Narita and coworkers previously
reported a spatial association between late-replicating re-
gions of the genome and H3K9me3 in SAHF, suggesting
that late-replicating regions marked with H3K9me3 are
repositioned during senescence to form SAHF [18]. Con-
cordant with this, H4K20me3 was enriched at H3K9me3-
marked late- and not late-replicating regions in both RS
and OIS [21, 59] (Fig. 3j). However, we observed under-
enrichment of H4K20me3 at those late-replicating regions
not marked by H3K9me3 (Fig. 3j). To obtain a more inte-
grated view of chromatin modifications in senescent cells,
(See figure on previous page.)
Fig. 3 ChIP-seq confirms enrichment of H4K20me3 at SAHF in senescent cells. a H4K20me3 enrichment at telomeric repeat sequences relative to
DNA input (left) and histone H4 (right) in proliferating (PRO; blue) and RS (red) cells. The % mapped H4K20me3/% mapped control was calculated
separately for each antibody and control. Mean value (n = 2) was plotted with standard error of the mean (SEM). b Quantitative PCR of H4K20me3
ChIP enrichment at 17p telomeres normalized to H4K20me3 ChIP enrichment at the β-globin locus in PRO and RS cells; error bars represent SEM of
three experiments (two experiments with the Millipore 04–079 antibody and one experiment with the Cell Signalling 5737 antibody). c Quantitative
PCR of H4K20me3 ChIP enrichment at 18q telomeres normalized to H4K20me3 ChIP enrichment at the β-globin locus in PRO and RS cells; error bars
represent SEM of three experiments (as in panel b). d Total number of overlapping H4K20me3 peaks identified with both antibodies (intersection) in
PRO and RS cells and significantly different (false discovery rate (FDR) <0.01) peaks between PRO and RS cells determined by DiffBind. e Total number
of base pairs comprising H4K20me3 peaks identified with both antibodies (intersection) in PRO and RS cells and significantly different (FDR <0.01)
peaks between PRO and RS determined by DiffBind. f Number of H4K20me3 DiffBind peaks from d that increase and decrease in RS cells relative to
PRO cells. g Observed overlap and expected overlap (enrichment compared to random) between base pairs covered by RS H4K20me3 DiffBind peaks
with base pairs covered by H3K9me3 peaks in senescent cells (empirical p < 0.001). h Observed overlap and expected (enrichment compared
with random) overlap between base pairs covered by RS H4K20me3 peaks (intersection of both antibodies) with base pairs covered by H3K9me3 in
senescent cells (empirical p < 0.001). i Mean RS and OIS H4K20me3 (normalized to histone H4) and OIS H3K9me3 (normalized to input) enrichment
profiles (read count) at a composite H3K9me3 peak. j Observed/expected overlap (log2 fold enrichment compared with random) between
base pairs covered by RS and OIS H4K20me3 peaks, RS H4K16ac peaks, DNA hypermethylated in RS regions, and DNA hypomethylated in
RS regions with H3K9me3-marked late-replicating regions, H3K9me3-marked not late-replicating regions, and late-replicating regions not
marked by H3K9me3. k Mean difference (RS − PRO) in H4K20me3 enrichment, H4K16ac enrichment, and percentage of methylated CpGs
at a composite H3K9me3-marked late replicating region
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we also performed these analyses on our previously
published datasets [21, 60]. A histone modification
linked to chromatin decompaction, H4K16ac [61], was
depleted from H3K9me3 and late-replicating regions in
RS cells. Conversely, these H3K9me3-enriched and
late-replicating regions tended to undergo DNA hypo-
methylation in RS, as indicated by under-enrichment of
DNA hypermethylated regions and enrichment in
hypomethylated regions (Fig. 3j). A composite analysis
of all H3K9me3 regions confirmed that these regions
lose DNA methylation and H4K16ac but gain
H4K20me3 in both RS and OIS (Fig. 3k; Additional
file 1: Figure S3h). In sum, H4K20me3 and H3K9me3
co-localize in RS and OIS cells at SAHF, whether
assessed by immunofluorescence or ChIP-seq, and recruit-
ment of H4K20me3 to these regions is specifically linked
to the presence of H3K9me3, not replication timing,
and coupled to coordinated changes in H4K16ac and
DNA methylation.
Next, we assessed differentially enriched H4K20me3
peaks identified by DiffBind at other features of the gen-
ome sequence. H4K20me3 was selectively enriched in
RS and OIS cells at some repeat elements, namely long
terminal repeats (LTRs) and satellite repeats (Fig. 4a).
Interestingly, although H4K20me3 was not enriched at
all transposable elements (long interspersed nuclear ele-
ments (LINEs), short interspersed nuclear element
(SINEs), LTRs, and DNA transposons (TEs)), it was
enriched at the more evolutionarily recent TEs and
under-enriched at the more ancient TEs (Fig. 4b, c) [62].
Similar results were obtained by analysis of LINEs only
(data not shown). Strengthening the relationship be-
tween H4K20me3 at some classes of repeats, we also ob-
served a marked enrichment of H4K20me3 at families of
repetitive coding genes in both RS and OIS (Fig. 4a). In-
deed, enrichment of H4K20me3 was most marked at a
relatively small number of genes (Fig. 4d), largely compris-
ing members of repetitive gene families, including genes
encoding ubiquitin-specific proteases, protocadherins, and
olfactory receptors, but most notably zinc finger proteins
and olfactory receptors (Fig. 4e–h; Additional file 1: Figure
S4a; Additional file 3: Datasets 1 and 2). Interestingly,
this massive enrichment of H4K20me3 at repetitive
genes was not markedly associated with their level of
expression in RS and OIS cells determined by RNA-seq
(Additional file 1: Figure S4b, c (coefficient of determin-
ation (R2) = 0.0108 and 0.001 for RS and OIS, respectively);
Additional file 2: Table S2).
The senescence program in part reflects a pattern of al-
tered gene expression characterized by the stable repres-
sion of proliferation-promoting genes and upregulation of
SASP genes [63]. Therefore, we compared gene expression
with enrichment of H4K20me3 at gene bodies (excluding
the aforementioned repetitive genes) in senescent cells. In
proliferating cells, there was no particular relationship
between gene expression and enrichment of H4K20me3
(Fig. 5a, b); H4K20me3 was depleted from genes regard-
less of their level of expression. In contrast, in both RS
and OIS cells, H4K20me3 was more enriched at bodies of
repressed genes than expressed genes (Fig. 5c, d). How-
ever, altered H4K20me3 did not correlate strongly with
changes in gene expression between proliferating and
senescent cells (Pearson correlation coefficient = −0.09
and 0.09 for OIS and RS, respectively, at genes that
significantly change expression between control and
senescence), suggesting that the switch from prolifera-
tion to senescence is accompanied by relative enrich-
ment of H4K20me3 mostly at repressed genes that do
not change expression between proliferation and senes-
cence. Scatter plots confirmed that the greatest in-
crease in H4K20me3 in RS and OIS occurred at genes
that were already low or unexpressed in proliferating
cells (Fig. 5e, f ).
SUV420H2 reinforces OIS and promotes tumor suppression
Since H4K20me3 increases in both RS and OIS cells, we
next sought to determine whether its elevated abundance
is sufficient to trigger cellular senescence. IMR90 cells
were stably infected with retroviruses encoding either of
the H4K20 histone methyltransferases SUV420H1 or
SUV420H2 or a control virus (Fig. 6a). Ectopic expression
of either SUV420H1 or H2 caused a marked elevation of
nuclear H4K20me3 abundance (Fig. 6b, c). Both enzymes
also produced a compensatory decrease in H4K20me1
abundance, similar to H-RASG12V (Figs. 1e, j and 6b). Of
note, SUV420H2, but not SUV420H1, induced upregula-
tion of H4K20me3 in a punctate pattern reminiscent of its
localization in senescent cells and more punctate DAPI
stain, suggestive of partial—but clearly incomplete—SAHF
formation (Figs. 2 and 6c). Moreover, by ChIP-seq we con-
firmed that IMR90 cells ectopically expressing SUV420H2
exhibited a fourfold increase in H4K20me3 peaks com-
pared with control cells (Additional file 1: Figure S5a–d).
H4K20me3 peaks in SUV420H2-expressing cells showed
a significant overlap with H4K20me3 peaks in RS and OIS
(Additional file 1: Figure S5E) and were similarly enriched
at some repetitive regions, including repetitive gene
bodies, LTRs, satellites, and some more evolutionarily
recent TEs (Additional file 1: Figure S5f, g). Despite these
elevated levels of nuclear H4K20me3 spatially distributed
similar to in RS and OIS cells, the SUV420H2- and
SUV420H1-infected cells continued to proliferate nor-
mally for many population doublings (Fig. 6d), maintained
cyclin A expression compared with control cells, and
failed to detectably induce p16INK4a (Fig. 6a, e). We con-
clude that elevated H4K20me3 is not sufficient to induce
acute proliferation arrest (or accelerate RS) in primary
IMR90 cells.
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Next, we asked whether SUV420H2 might enforce es-
tablishment and/or maintenance of OIS. Stably infected
control cells or cells ectopically expressing SUV420H2
(from Fig. 6a–d) were subjected to secondary infection
with either an empty vector retrovirus or virus encoding
oncogenic H-RASG12V and assayed at sequential time
points for markers of proliferation and senescence.
Within 5 days of infection with H-RASG12V, both con-
trol and ectopic SUV420H2-expressing cells displayed
features of cell cycle arrest (decreased expression of cyc-
lin A and PCNA and reduced pRB phosphorylation
(based on increased mobility in SDS-PAGE and reduced
reactivity with anti-ppRB (Ser780)) and markers of
senescence establishment (reduced expression of lamin
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B1, induction of p16INK4a and p21) (Fig. 6f ). Decreased
expression of EZH2, a histone methyltransferase that
deposits H3K27me3 and whose downregulation contrib-
utes to upregulation of p16INK4a in senescence [64],
was also observed in both control and SUV420H2-
expressing cells upon H-RASG12V infection. Both
control and ectopic SUV420H2-expressing cells infected
with H-RASG12V displayed robust SA β-gal staining,
confirming comparable induction of senescence in both
cases (Additional file 1: Figure S6a). However, on exam-
ination of specific cell cycle markers 15 days after H-
RASG12V infection, notable differences were observed
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between the control and ectopic SUV420H2-expressing
cells despite equivalent expression of H-RASG12V. Com-
pared with control cells, SUV420H2-expressing cells ex-
hibited enhanced repression of cyclin A, PCNA, lamin B1,
EZH2, and pRB hypophosphorylation and upregulation of
p16INK4a and p21. Consistent with enhanced senescence
in SUV420H2-expressing cells and compared with con-
trol/H-RASG12V cells, these cells consistently exhibited a
lower frequency of dense crystal violet stained cell colonies
appearing >15 days after infection with H-RASG12V
(Additional file 1: Figure S6b). These results suggest that,
although elevated H4K20me3 is not sufficient to arrest
unstressed normal proliferating cells nor to accelerate RS
or enhance the induction of OIS, high levels of SUV420H2
and H4K20me3 can enhance stability of the OIS program
in IMR90 cells.
To test the proliferation and hence tumor suppressive
properties of SUV420H2 and H4K20me3 in another model,
we turned to human HT1080 cells [65]. The cell of origin
of these fibrosarcoma cells is presumably phenotypically
closer to mesenchymal IMR90 fibroblasts than is the
case for most commonly used epithelial-derived carcin-
oma cell lines. Moreover, these cells harbor an activated
N-RASQ61K allele and homozygous deletion of p16INK4a
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[66, 67]. Consistent with a tumor suppressive role for
SUV420H2 and/or H4K20me3, HT1080 cells showed
decreased expression of SUV420H2 compared with prolif-
erating and senescent IMR90 (Fig. 7a) and decreased
H4K20me3 compared with RS IMR90 (Fig. 7b). In fact,
mining of data in the cBioPortal for Cancer Genomics
database confirmed that expression of SUV420H2 is typic-
ally downregulated in tumor compared with corresponding
normal tissue (Fig. 7c). To test whether downregulation of
SUV420H2 and H4K20me3 confers a direct proliferative
advantage on these transformed cells, HT1080 cells
were infected with either an empty vector retrovirus or
virus encoding SUV420H2 and assayed for H4K20me3
abundance. As anticipated, ectopic expression of
SUV420H2 induced an elevated level of H4K20me3 in
the HT1080 cells (Fig. 7d; Additional file 1: Figure S6c).
Ectopic expression of SUV420H2 and the commensur-
ate increase in abundance of H4K20me3 failed to
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restore full senescence in the HT1080 cells (data not
shown). Cell cycle analysis by propidium iodide staining
and pulse labeling with 5-bromo-2′-deoxyuridine (5-
BrdU) revealed a modest decrease in S phase and in-
crease in G2/M in SUV420H2-expressing cells (Fig. 7e,
f; Additional file 1: Figure S6d). The altered cell cycle
distribution of the SUV420H2-expressing HT1080 cells
was paralleled by a diminished rate of proliferation
compared with control HT1080 cells (Fig. 7g). To test
whether these effects of SUV420H2 depend on catalytic
activity, we tested a SUV420H2 mutant (SUV420H2(-
N182A,Y217A)) previously reported to lack methyl-
transferase activity in mouse [68, 69]. Although this
mutant was modestly under-expressed relative to the
wild-type protein (Additional file 1: Figure S6e), it was
profoundly impaired in its ability to elevate H4K20me3
in HT1080 cells and failed to show a trend towards de-
creased cells in S phase and increased cells in G2/M
phase and completely failed to slow the growth of
HT1080 cells (Additional file 1: Figure S6f, g), suggesting
that the proliferation-inhibitory effects of SUV420H2
depend on methyltransferase activity.
To test whether elevated SUV420H2 and H4K20me3
can restrain tumor growth, HT1080 cells stably infected
with either control or SUV420H2 retrovirus were
injected subcutaneously into the flanks of 6-week-old
CD-1 nude athymic mice (Crl:CD1-Foxn1nu) and tumor
volumes measured at regular intervals. Mice injected
with control-infected HT1080 cells formed significantly
larger tumors than mice injected with HT1080 cells har-
boring elevated H4K20me3 through ectopic expression
of SUV420H2 (Fig. 7h). Indeed, the maximum growth
rate for tumors derived from control HT1080 cells was
3.8 times faster than that of the SUV420H2 expressing
HT1080 cells (5.6 mm3/day versus 1.5 mm3/day; p =
0.0047; Fig. 7i). In sum, although SUV420H2 is unable
to induce frank senescence in these p16INK4a-deficient
cells, elevated levels of SUV420H2 and H4K20me3
modestly impair proliferation in culture and markedly
suppress tumorigenesis in xenograft assays.
Discussion
Several previous studies have pointed to the functional
significance of H4K20me3 in senescent and progeroid
cells [33, 34]. Here we have confirmed that H4K20me3
is also upregulated in senescent cells in vivo, specifically
OIS melanocytes. Compared with proliferating cells,
H4K20me3 is relatively enriched in both RS and OIS
cells in at least three features of the genome. First,
based on immunofluorescence and ChIP-seq analysis,
H4K20me3 is enriched in heterochromatic SAHF. Here,
H4K20me3 co-localizes with another heterochromatic
modification, H3K9me3. H3K9me3 is indirectly respon-
sible for recruitment of SUV420H2 and H4K20me3 to
chromatin [49, 55], and in SAHF, H4K20me3 specifically
overlapped with H3K9me3, not late-replicating DNA.
Thus, H3K9me3 is likely responsible for recruitment of
H4K20me3 to SAHF. Previously, we showed that telo-
meres are largely excluded from SAHF in RS cells [70].
In line with this initially surprising observation and en-
richment of H4K20me3 in SAHF, we show here that
telomeres and subtelomeres do not gain H4K20me3 in
RS cells but rather show a tendency to lose this modifi-
cation. Together, our results and those of Narita and
coworkers [18] indicate that SAHF are assembled from
late-replicating regions of the genome marked with
H3K9me3 and H4K20me3, but excluding some late-
replicating sequences, such as telomeres [70]. These
H3K9me3-marked SAHF regions are also depleted of
H4K16ac and DNA methylation. The observation that
ectopic expression of SUV420H2 in cells creates
H4K20me3 foci in DAPI-dense SAHF-like structures,
albeit not as well formed as in RS or OIS cells, suggests
that SUV420H2/H4K20me3 is partly causative for for-
mation of SAHF. However, changes in other modifica-
tions, H4K16ac and DNA methylation, might be
essential for full SAHF formation.
Second, in RS and OIS cells, H4K20me3 is markedly
enriched at the gene bodies of some clusters of genic
repeats, such as genes encoding ZNF proteins, olfac-
tory receptors, and protocadherins, and also some
non-genic repeats, such as LTRs, satellites, and other
evolutionarily recent TEs. In fact, previous studies in
proliferating cells have shown some basal enrichment
of H4K20me3 at transcriptionally silent and/or repeti-
tive sequences, including ZNF genes [44, 49, 55–57].
At such sequences, H4K20me3 and other heterochro-
matin marks have been proposed to suppress recombin-
ation [43–46]. Conceivably, the increase in H4K20me3 at
gene repeats in senescent cells reflects this role in sup-
pression of recombination between homologous repeat
sequences. Similarly, at some non-genic repeats, ele-
vated H4K20me3 might be involved in suppression of
recombination. In addition, in light of recent reports
indicating a tendency for expression and transposition
of retroelements in senescent and aged cells [71–73],
H4K20me3’s preferential targeting to the most evolu-
tionarily recent and retrotransposition-competent TEs
(LINEs) might reflect a role in suppression of retrotran-
sposition, another threat to genome stability.
Third, in contrast to proliferating cells, RS and OIS
cells show marked enrichment of H4K20me3 at bod-
ies of repressed genes relative to expressed genes.
Interestingly, however, this does not predominantly
reflect increased H4K20me3 at genes that are
expressed in proliferating cells and repressed in senes-
cent cells. Rather, in senescent cells, H4K20me3 is
gained mostly at genes that are lowly or unexpressed
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in both proliferating and senescent cells. This sug-
gests that H4K20me3 does not play the role of a
“switch” between proliferating and senescent cells but
perhaps is more involved in a “lock down” of the
already-repressed epigenome.
Consistent with this idea, while elevated SUV420H2
and H4K20me3 did not detectably impact prolifera-
tion of primary human fibroblasts, they did reinforce
OIS-associated proliferation arrest. Moreover, elevated
SUV420H2 and H4K20me3 markedly reduced tumorigen-
icity of oncogenic N-RASQ61K-expressing HT1080 cells
[74]. Together, these results suggest that increased
H4K20me3 does not directly induce senescence in normal
human cells but can reinforce senescence and slow tumor
progression in oncogene-expressing cells. While the
underlying mechanisms remain to be determined, based
on analysis of the ChIP-seq data, we speculate that in-
creased H4K20me3 can stabilize both the epigenome and
the genome and hence suppress epigenetic changes and
genome rearrangements that promote clonal outgrowth in
environments with strong selective pressure, for example,
escape from OIS in vitro or clonal evolution of tumors
in vivo. At least in the case of benign human nevi, OIS
cells can persist in the tissue for decades [3, 51].
Long-term maintenance of tumor suppression in
oncogene-expressing senescent cells likely depends on
an exceptionally high level of epigenomic, transcrip-
tomic, and genomic stability; not only because an acti-
vated oncogene is one step on the road to cancer, but
also because such oncogenes often possess the ability
to wreak further genetic and epigenetic havoc on the
host cell. Accordingly, we hypothesize that increased
H4K20me3 in senescent cells and aged tissues acts as
a barrier to cancer through enhanced preservation of
epigenetic and genetic stability, for example, by suppress-
ing genome rearrangements that might allow escape from
senescence and, hence, tumor progression.
Elevated H4K20me3 also caused accumulation of
HT1080 cells in G2/M phase of the cell cycle and modestly
slowed proliferation in HT1080 cells. The mechanism
underlying this is unknown, although it might reflect the
known role of histone H4 methylation in kinetochore as-
sembly [75]. If so, elevated H4K20me3 might have multiple
tumor suppressor functions.
Previous reports showed that abundance of H4K20me3
is increased in senescent cells, progeroid cells, and aged
tissues [33–35] but decreased in cancer cells [36–39].
Senescent cells are known to accumulate in some aged
tissues [76–78], suggesting that the increase in aged
tissue might reflect accumulation of senescent cells. Al-
ternatively, the increase in aged tissue might reflect a
stress response distinct from senescence, as has been
suggested for some other histone modifications [79]. On its
own, elevated H4K20me3 is unable to induce senescence
and proliferation arrest. This is not surprising given the
concerted changes in H4K16ac and DNA methylation de-
scribed here, as well as of other histone modifications [20].
However, elevated SUV420H2 and H4K20me3 can
reinforce senescence-associated proliferation arrest and re-
tard tumorigenesis of cells harboring an activated onco-
gene. Thus, accumulation of H4K20me3 in senescent cells
and aged tissues might counter accumulation of pre-
malignant oncogene-expressing cells and other damaged
cells in aged tissues [80]. By extension, this can explain why
H4K20me3 is decreased in cancer cells [36–40]. Downreg-
ulation of H4K20me3’s tumor suppressive function in
oncogene-expressing and other damaged cells that accumu-
late with age is expected to confer a growth and selective
advantage on the nascent cancer cell. So, while many
unanswered questions remain, this study advances our
understanding of the complex and contrasting regulation of
H4K20me3 in senescence, aged, and cancer cells.
Conclusions
This first comprehensive description of H4K20me3 in
the chromatin landscape of senescent cells is a critical
landmark contribution to understanding its previously
invoked diverse functions in cell senescence, genome
stability, ageing, and tumor suppression. These results
corroborate the emerging view of chromatin in senes-
cent cells as a specialized landscape that underpins the
stability of the senescence phenotype. Specifically, these
results implicate SUV420H2 and H4K20me3 in stable
oncogene-induced senescence-associated proliferation
arrest and tumor suppression.
Methods
Human nevus tissues
Human nevus tissues were fixed in 10 % (vol/vol) buff-
ered formalin for 1–3 days and embedded in paraffin
following routine histology procedure. Sections of unre-
markable human skin and benign nevi were evaluated by
a board-certified dermatopathologist (HW).
Cell culture
IMR90 human diploid fibroblasts were obtained from
the Coriell Institute (Camden, NJ, USA) and cultured
in 3 % oxygen in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 20 % (vol/vol) fetal bovine
serum, 2 mM L-glutamine, 25 U/ml penicillin, and
25 μg/ml streptomycin according to the suggested
guidelines. IMR90 cells were considered RS when no
proliferation was observed for a 2-week period following
the final passage and most cells displayed senescence
markers (SA β-gal, 5-ethynyl-2′-deoxyuridine (EdU)
incorporation-negative, p16INK4a expression, SAHF). For
induction of quiescence, cells were transferred to growth
medium containing reduced serum (DMEM+ 0.1 % fetal
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bovine serum, 2 mM L-glutamine, 25 U/ml penicillin,
25 μg/ml streptomycin). Seventy-two hours after split-
ting, the cells were harvested and assayed for hallmarks
of proliferation arrest and senescence. The cells were
considered quiescent if they no longer proliferated but
also did not exhibit markers of senescence (SA β-gal ac-
tivity, p16INK4a induction). HT1080 human fibrosar-
coma cells were obtained from Sigma-Aldrich (St.
Louis, MO, USA) and cultured in DMEM supple-
mented with 10 % fetal bovine serum, 2 mM L-glutam-
ine, 25 U/ml penicillin, and 25 μg/ml streptomycin
according to the suggested guidelines.
Plasmids and retroviral infection
The following plasmids were obtained as gifts of Bill
Hahn and Bob Weinberg: pBABE-puro, pBABE-puro-H-
RASG12V, pBABE-neo, and pBABE-neo-H-RASG12V.
pBABE-puro-Myc-SUV420H1 and pBABE-puro-Myc-
SUV420H2 were generated by subcloning the respective
full-length open reading frames from pC1-HA-SUV420H1
and pC1-HA-SUV420H2 (obtained as gifts of D. Alan
Underhill, University of Alberta) into pBABE-puro-Myc
using conventional molecular biology methods. The enzy-
matically inactive form of human SUV420H2, SUV420H2-
N182A,Y217A [69], was generated by site-directed mutagenesis
PCR using pBABE-puro-Myc-SUV420H2 as template. For
induction of OIS, IMR90 cells were infected with control
pBABE-neo or pBABE-neo-H-RASG12V and selected
in 500 μg/ml neomycin. H-RASG12V-expressing cells
were considered OIS 8–10 days later, at which point
they expressed the same markers of senescence as RS
cells (see above).
Immunofluorescence, SAHF, and SA β-gal staining
Indirect immunofluorescence and SAHF staining assays
were performed according to standard protocols and/or as
previously described [15, 16, 81]. Antibodies raised against
H4K20me3 (Millipore, 04–079; Active Motif, 39180), PML
(Santa Cruz, sc-5621), 53BP1 (Cell Signaling Technology,
4937), γ-H2AX (Millipore, 05–636), H3K9me3 (Abcam,
ab8898), and Myc (Santa Cruz, sc-40) were obtained from
the respective vendors. SA β-gal staining was performed as
previously described [76].
Western blotting
Whole cell lysates were fractionated by SDS-PAGE,
immobilized to PVDF, and subjected to Western blotting
as previously described [81]. Antibodies raised against
Ras (BD Biosciences, 610001), cyclin A (Santa Cruz, sc-
751), p16INK4a (BD Biosciences, 551154), β-actin
(Sigma, A1978), H4K20me3 (Millipore, 04–079 (see
Additional file 1: Figure S1c for specificity); Active Motif,
39671 and 39180), histone H4 (Active Motif, 39269),
H4K20me1 (Millipore, 04–735), SUV420H2 (Abcam,
ab91224), GAPDH (Cell Signaling Technology, 2118),
Myc (Santa Cruz, sc-40), H4K20me2 (Active Motif,
39174), lamin A/C (Cell Signaling Technology, 2032),
lamin B1 (Abcam, ab16048), PCNA (Cell Signaling
Technology, 2586), p21 (Abcam, ab7960), Rb (Cell Signal-
ing Technology, 9309), phospho-Rb Ser780 (Cell Signaling
Technology, 9307), and EZH2 (Cell Signaling Technology,
5246) were obtained from the respective vendors.
Immunohistochemistry
This was performed as described previously [81]. Briefly,
formalin-fixed, paraffin-embedded sections were depar-
affinized, rehydrated, and blocked for endogenous perox-
idases and underwent antigen retrieval according to
antibody specifications. Tissues were incubated over-
night with the following primary antibodies: anti-human
melan A clone A103 (M7196; Dako), anti-H4K20me3
(04–079, Millipore and cs5737, Cell Signaling). Second-
ary antibodies used for 3,3′-diaminobenzidine (DAB)-
based immunohistochemistry were either EnVision +
System-HRP Labeled Polymer Anti-mouse (K4001;
Dako) or EnVision + System-HRP Labeled Polymer
Anti-rabbit (K4003; Dako) based on primary antibody
host species. Peroxidase activity was revealed using DAB
(K3468; Dako). Samples were then counterstained with
hematoxylin, dehydrated, and coverslipped.
Mass spectrometry
Quantitative mass spectrometry was performed as
previously described [82]. Briefly, total histones were
acid extracted from proliferating and replicative sen-
escent IMR90 cells with H2SO4 and treated with pro-
pionyl anhydride. Bulk histones were then digested
with trypsin, labeled with d10-propionic anhydride,
separated by HPLC, and subjected to LC-MS/MS.
The relative abundance of each histone H4 lysine 20
modification was derived using the EpiQuant analysis
package [83].
Chromatin immunoprecipitation
Proliferating and RS, control and OIS, and control and
SUV420H2 IMR90 cells were cross-linked with 1 % for-
maldehyde, quenched with 125 mM glycine, detached by
scraping, washed with phosphate-buffered saline (PBS),
and collected by centrifugation. Cross-linked cells were
pre-extracted with (1:1) modified nuclear lysis buffer
(mNLB):immunoprecipitation dilution buffer (IPDB)
(35 mM Tris–HCl pH 8.0, 75 mM NaCl, 5.5 mM EDTA
pH 8.0, 3 mM EGTA pH 8.0, 0.5 % SDS, 0.5 % Triton X-
100) supplemented with 10 μg/ml aprotinin, 5 μg/ml
leupeptin, and 50 μg/ml PMSF and sonicated at a dens-
ity of 2 × 107 cells per 1 ml cold (1:1) mNLB:IPDB plus
inhibitors. Sonicated chromatin solutions were cleared
by centrifugation, diluted with IPDB (20 mM Tris–HCl
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pH 8.1, 150 mM NaCl, 2 mM EDTA, 1 % Triton X-100,
0.01 % SDS) to a final mNLB:IPDB ratio of 1:10, trans-
ferred to microcentrifuge tubes containing antibodies
(from Millipore (04–079) and Cell Signaling Technology
(5737); Additional file 1: Figure S1c, d) pre-bound to
Dynabeads M-280 Sheep anti-Rabbit IgG magnetic beads
(Life Technologies), and incubated overnight at 4 °C with
rotation. The ChIP reactions were washed twice with
IPDB, once with high salt wash buffer (20 mM Tris–HCl
pH 8.0, 500 mM NaCl, 2 mM EDTA, 0.1 % SDS, 1 %
Triton X- 100), once with LiCl wash buffer (10 mM Tris–
HCl pH 8.1, 250 mM LiCl, 1 mM EDTA, 1 % NP-40, 1 %
deoxycholic acid), and twice with 1× TE. Beads were aspi-
rated to dryness, resuspended in 500 μl IP elution buffer
(50 mM Tris–HCl pH 8.0, 300 mM NaCl, 10 mM EDTA
pH 8.0, 1 % SDS) and 0.5 μl 100 mg/ml RNase A and in-
cubated at 65 °C for 4–6 h. To each tube, 6 μl of 20 mg/
ml proteinase K was added and the tubes were incubated
at 45 °C for 12 h. ChIP DNA was purified by phenol/
chloroform extraction with ethanol precipitation, resus-
pended with 20 μl nuclease-free dH2O, and quantified
using the Qubit dsDNA HS Assay Kit and a Qubit
fluorometer (Life Technologies).
ChIP-qPCR of telomeric-adjacent sequences
The 17p qPCR assay is designed 426 nucleotides away
from the beginning of the TTAGGG repeat tract. There-
fore, when used to measure H4K20me3, the assay mea-
sures enrichment in both the telomere repeat tract and
the telomere proximal region. The same is true of the
18q qPCR assay, which is located 444 nucleotides away
from the TTAGGG repeat tract. Enrichment at each
telomere was normalized to the β-globin locus (a locus
that shows no substantial enrichment in either prolifer-
ating or RS cells by ChIP-seq (data not shown)), i.e.,
[tel]ENRICHMENT = [tel]IP/[β-globin]IP.
17p primers were: 17pA (forward), GTTTTCACCTG
TTTTGGTCTTC; 17pB (reverse), GGATCCTTGCAC
AGGAATAAAC. 18q primers were: 18qA (reverse)
TGACAGTGGTGTCCAGTGGT; 18qC (forward), CAC
AGGGATGGTTAGGTATCTC. Beta-globin primers were:
forward, AGGACAGGTACGGCTGTCATC; reverse, TTT
ATGCCCAGCCCTGGCTC.
Next-generation sequencing and analysis
ChIP-sequencing libraries were prepared using 10 ng
ChIP DNA, adaptors and primers from Illumina, and
the NEBNext® ChIP-Seq Sample Prep Master Mix Set 1
(New England Biolabs) according to the manufacturer’s
instructions. Libraries were hybridized to Illumina flow-
cells using the TruSeq SR Cluster v2–cBot-GA kit and
cBot instrument and subjected to 75–76 cycle, single-
end sequencing using the TruSeq SBS Kit v5-GA kit and
Genome Analyzer IIx sequencer (Illumina).
RNA-seq
Paired-end reads were aligned to the human genome
(hg19) using a splicing-aware aligner (TopHat2) [84]. Only
unique reads were retained (Additional file 2: Table S1).
Reference splice junctions were provided by a reference
transcriptome (Ensembl build 73) and novel splicing junc-
tions determined by detecting reads that spanned exons
that were not in the reference annotation. Aligned reads
were processed to assemble transcript isoforms and
abundance was estimated using the maximum likeli-
hood estimate function (cuffdiff ) from which differen-
tial expression and splicing are derived [85]. Genes of
significantly changing expression were defined as FDR
corrected p value ≤0.05.
WGBS-seq
Whole genome bisulfite sequencing data were aligned
and processed to hg19 as [21]. The percentage methyla-
tion at each CpG site was calculated as [21].
ChIP-seq
ChIP-seq single-end reads were aligned to the human
genome (hg19) using the Bowtie2 alignment software
[86] (Additional file 1: Table S2). Regions of H4K20me3
and H4K16ac occupancy were determined using SICER
(v1.1) [87] using a redundancy threshold of 1, window
size of 200 bp, fragment size of 150, effective genome
fraction of 0.75, gap size of 200, and R of 0.01. Histone
H4 was used as the control for the RS and OIS models
and input DNA was used as the control for the
SUV420H2 ectopic expression model. For each condi-
tion (proliferating and senescent), the intersection of
peaks called using both antibodies was determined using
the bed tools intersect tool [88].
Differentially bound regions were determined using the R
(v3.0.2) package DiffBind (v1.8.3) [58]. The count parame-
ters used were: minOverlap = 1, bCorPlot = FALSE, inser-
tLength = 150, score =DBA_SCORE_READS_MINUS. The
analysis parameters used were: bTagwise = FALSE, bFullLi-
brarySize = TRUE, bCorPlot = FALSE, method =DBA_DE-
SEQ2. Regions of significantly differential occupancy were
defined as FDR corrected p value <0.01.
ChIP-seq signal
The ChIP-seq signal for any given window was calcu-
lated as the total number of fractional reads within a
window divided by the window length, with the product
divided by the total number of reads in the dataset di-
vided by one million. For a normalized window the
ChIP-seq signal of the control was subtracted from
treatment. In Fig. 4b, g the values were normalized by
the addition of the lowest signal to all signals. For all
plots the pooled reads from all replicates were used.
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H3K9me3 peaks
The senescent H3K9me3 peaks were obtained from the
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.-
nih.gov/geo/query/acc.cgi?acc=GSE38442) and converted
to hg19 using UCSCs liftover tool [89].
H3K9me3 peak enrichment composite profiles
To generate H3K9me3 peak enrichment profiles, the
area between each H3K9me3 peak was divided into 50
windows of equal size (each corresponding to 2 % of the
total peak region). Fifty additional 100-bp windows were
prepended (appended) to the start (end) of the peak re-
gion to provide genomic context. The average normalized
ChIP-seq signal was then calculated for each window.
H4K20me3 and H3K9me3 were normalized to histone H4
and input DNA, respectively.
SAHF composite profiles
To generate SAHF enrichment profiles, the area between
each intersected late replicating region and H3K9me3
peak was divided as the H3K9me3 peak enrichment
composite profiles. The mean difference (replicative sen-
escent minus proliferating or OIS minus control) in nor-
malized ChIP-seq signal and percentage methylated
CpGs was then calculated for each window. H4K20me3,
H4K16ac, and H3K9me3 were normalized to histone
H4, histone H4, and input DNA, respectively.
Spearman correlation coefficients for expression versus ChIP
enrichment
To generate Spearman values the ChIP-seq signal was
calculated at the gene body of all genes within the gene
set. Spearman values were calculated using the R (v3.0.2)
method cor.test.
Overlap plots
The overlap between two sets of regions was determined
using the bedtools tool intersectBed under default pa-
rameters [88].
Observed-to-expected overlap
Overlaps were computed on a per base pair basis be-
tween two datasets (A and B). For every region within
A, the number of base pairs that were occupied by a
region within B was computed. A permutation test
was performed in order to determine the background
genomic average expected overlap. We generated
10,000 sets of regions with properties (length distribu-
tion and chromosome distribution) equal to set B.
Randomly generated regions of B were prevented from
being generated within unsequenced regions of the gen-
ome (as defined by the UCSC mapping and sequencing
track - "gap"). The overlap of A and B was repeated for
each randomly generated set of B to determine the
average expected random overlap. P values were estimated
empirically from the observed overlaps of the randomly
generated sets.
Genomic features
Coding genes were defined as all Ensembl genes (version
73) of Gene Biotype protein coding and status known.
Promoters were defined as the region spanning ±2 kb of
the outermost transcription start site of each coding
gene. Exons, 3′ UTRs, and 5′ UTRs were defined as the
corresponding Ensembl (version 73) regions for known
coding genes, and introns as the corresponding genic
but not intronic regions. RNA genes were defined as all
Ensembl non-coding, non-pseudo genes. Repetitive ele-
ments and CpG islands were obtained from UCSC
(hg19). CpG island shores were defined as the 2 kb
flanking the CpG island and CpG island shelves as the
2 kb flanking the shores [90]. Hypermethylated and
hypomethylated regions were obtained from GEO (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48580 =
GSE48580) and converted to hg19 using UCSCs liftover
tool [89]. Early/late replicating regions were mapped previ-
ously [21] and converted to hg19 using UCSCs liftover tool
[89].
H4K20me3 abundance at telomeres by ChIP-seq
To map telomeric reads, a 1-kb telomeric repeat
(TTAGGG) sequence was generated and reads aligned
using the Bowtie2 alignment software. The percentage of
mapped reads for H4K20me3, histone H4, and input
was calculated for proliferating and senescent cells. The
ratio of percentage mapped reads H4K20me3/percentage
mapped reads control was then plotted.
H4K20me3 enrichment at TE subtypes by evolutionary order
To determine the enrichment at TE subtypes, for each
set of DiffBind peaks, the observed/expected fold overlap
with each TE subtype was calculated. TE subtypes
were obtained from UCSC. Next, the evolutionary
order of each TE subtype was determined as described
previously [62].
The Cancer Genome Atlas SUV420H2 expression
The Cancer Genome Atlas (TCGA; http://cancergenome.-
nih.gov) SUV420H2 RNA-seq expression Z scores for
each cancer type and sample was obtained from cBIOPor-
tal (http://www.cbioportal.org/about_us.jsp). Boxplots in
Fig. 7c were generated using R (v3.0.2). The bottom and
top of the boxes correspond to the 25th and 75th percen-
tiles respectively, and the internal band is the median. The
plot whiskers correspond to the most extreme value
within 1.5 x interquartile range.
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cBIOPortal definition of Z scores
For mRNA and microRNA expression data, we typically
compute the relative expression of an individual gene
and tumor to the gene’s expression distribution in a
reference population. The reference population was ei-
ther all tumors diploid for the gene in question or,
when available, normal adjacent tissue. The returned
value indicates the number of standard deviations away
from the mean of expression in the reference popula-
tion (Z score). This measure is useful in determining
whether a gene is up- or downregulated relative to the
normal samples or all other tumor samples.
Xenograft experiments
Five-week-old, female CD-1 athymic nude mice
(Crl:NU-Foxn1nu) were obtained from Charles River La-
boratories and equilibrated to the institute animal facility
for 1 week. At 6 weeks of age, mice were injected sub-
cutaneously in the flank with 2 × 106 HT1080 cells stably
infected with either control or SUV420H2 retrovirus
and suspended in 100 μl sterile PBS. Mice were moni-
tored daily for any adverse clinical signs and tumor size
measurements obtained approximately every two days
using manual calipers. Mice were culled when tumors
reached 10 mm in any dimension and tumors were col-
lected for histopathological and biochemical evaluation.
To calculate tumor volume (mm3), the length (L) and
width (W) of the tumor was measured with calipers and
tumor volume calculated from L ×W×W (where W is
the smaller of the two measurements).
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